Reply to: “Herpes zoster seven days after SARS-CoV-2 vaccination in a patient with ankylosing spondylitis under adalimumab” by Josef Finsterer

Several guidelines suggest investigating the incidence and prevalence of vaccine-preventable infections in adult patients with autoimmune or inflammatory diseases; consequently, the effect and safe-ty issues of vaccination are under careful examination. Moreover, immunosup-pression and immunodeficiency were con-traindications for the previously available vaccine in the past years, thus live zoster vaccine was originally recommended for immunocompetent adults aged ≥50 years, leading to an unmet need for vaccination against HZ in immunocompromised adults. Considering all these efforts and the current pandemic challenge, we be-lieve that now more than ever we are asked to quickly detect potential adverse events, even extremely rare and mild ones, and to face them, in order to support the robust pharmacovigilance campaign for SARS-CoV2 vaccination.